BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "sell (d-)" rating reiterated by research analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.
A number of other research analysts have also weighed in on the company. JPMorgan Chase & Co. increased their price target on BioNTech from $116.00 to $121.00 and gave the stock a "neutral" rating in a research note on Monday, September 22nd. HC Wainwright reiterated a "buy" rating and set a $136.00 target price on shares of BioNTech in a research report on Monday, September 8th. Bank of America increased their price objective on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Morgan Stanley cut their price objective on shares of BioNTech from $133.00 to $131.00 and set an "overweight" rating on the stock in a report on Friday. Finally, Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an "overweight" rating in a research note on Tuesday, August 5th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $134.32.
Get Our Latest Stock Analysis on BioNTech
BioNTech Trading Up 0.2%
NASDAQ:BNTX traded up $0.25 on Tuesday, reaching $102.55. The stock had a trading volume of 217,329 shares, compared to its average volume of 950,002. The company has a market cap of $24.65 billion, a price-to-earnings ratio of -64.21 and a beta of 1.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm's fifty day moving average is $104.32 and its two-hundred day moving average is $103.68. BioNTech has a 12-month low of $81.20 and a 12-month high of $129.27.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The firm had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech's revenue for the quarter was up 102.6% on a year-over-year basis. During the same quarter last year, the company posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Equities analysts expect that BioNTech will post -3.88 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the 1st quarter valued at about $36,000. LRI Investments LLC raised its stake in shares of BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after purchasing an additional 312 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. raised its stake in shares of BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock valued at $61,000 after purchasing an additional 472 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of BioNTech by 40.8% during the third quarter. GAMMA Investing LLC now owns 784 shares of the company's stock valued at $77,000 after purchasing an additional 227 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
